The need for positron emission tomography (PET)-radioligands that are sensitive to changes in endogenous serotonin (5-HT) levels in brain is recognized in experimental and clinical psychiatric research. We recently developed the novel PET radioligand [ 11 C]AZ10419369 that is highly selective for the 5-HT 1B receptor. In this PET-study in three cynomolgus monkeys, we examined the sensitivity of [ 11 C]AZ10419369 to altered endogenous 5-HT levels. Fenfluramine-induced 5-HT release decreased radioligand binding in a dose-dependent fashion with a regional average of 27% after 1 mg/kg and 50% after 5 mg/kg. This preliminary study supports that [ 11 C]AZ10419369 is sensitive to endogenous 5-HT levels in vivo and may serve as a tool to examine the pathophysiology and treatment of major psychiatric disorders. Synapse 64:573-577,
INTRODUCTION
Alterations in neurotransmitter levels in brain can be detected in a noninvasive manner using positron emission tomography (PET). The methodology has long since been successfully applied to study altered dopamine (DA) levels in the human brain following drug challenges (Volkow et al., 1994) or physiological stimuli (Koepp et al., 1998) . Similar examinations of serotonin (5-HT) levels have however been precluded by the lack of suitable radioligands. Of available serotonergic radioligands, the 5-HT 1A antagonist [ 18 F]MPPF has been the most promising with regard to changes in endogenous 5-HT levels in the rat and cat brain (Aznavour et al., 2006; Zimmer et al., 2002 Zimmer et al., , 2003 , but the findings have not been consistently confirmed in monkey and human subjects (Derry et al., 2006; Praschak-Rieder et al., 2004; Sibon et al., 2008; Udo de Haes et al., 2002 .
Of the fourteen 5-HT-receptor subtypes, the 5-HT 1B receptor is of particular interest for radioligand development since this primarily presynaptic receptor regulates the release of 5-HT (Engel et al., 1986; Göthert et al., 1987; Maura et al., 1986) and thus should be sensitive to 5-HT levels. We recently developed [ 11 C]AZ10419369, a selective antagonist radioligand for the 5-HT 1B receptor subtype (K d 5 0.8 nM human) as confirmed by autoradiography and initial PET studies in monkey and human subjects (Pierson et al., 2008) . In monkeys [ 11 C]AZ10419369 binding was reversible, making this radioligand suitable for quantitative PET-determination of 5-HT 1B receptor binding and drug occupancy in vivo.
In this PET-study in three cynomolgus monkeys, we evaluated the sensitivity of [ 11 C]AZ10419369 to fenfluramine-induced elevation of endogenous 5-HT levels.
MATERIALS AND METHODS
[ 11 C]AZ10419369 was produced as has been described previously (Pierson et al., 2008) . PET measurements were performed in an HRRT PET-system (Siemens Molecular Imaging) with an in plane resolution of 1.5 mm FWHM in the center of the field of view (Varrone et al., 2009) . The study was approved by the Animal Ethics Committee of the Swedish Animal Welfare Agency (Dnr 260/07). A total of 12 PET measurements were performed in three female cynomolgus monkeys. Each monkey was examined four times with [ 11 C]AZ10419369 on two experimental days. On each day, a baseline measurement was followed by a displacement measurement with fenfluramine 1.0 or 5.0 mg/kg. PET measurements were performed 3 h apart and a minimum of 1 month elapsed between experimental days.
The racemate (6)-fenfluramine was dissolved in saline and infused i.v. over 5 min starting 15 min after i.v. injection of [ 11 C]AZ10419369. The doses of (6)-fenfluramine (1.0 and 5.0 mg/kg) are expressed as relative to the free base.
Anesthesia was initiated by i.m. injection of ketamine hydrochloride ($10 mg/kg, Ketaminol 1 , Intervet AB) and maintained with sevoflurane (1.5-8%, Abbott Scandinavia AB) after intubation. On one of the six experimental days, intubation of the monkey was not successful, and anesthesia was maintained by continuous i.v. infusion (1.0 ml/kg/h) of a mixture of ketamine hydrochloride (4.0 mg/kg/h, Ketalar 1 , Pfizer AB) and xylazine hydrochloride (0.80 mg/kg/h, Rompun 1 Vet., Bayer A/S). Standardized T1-weighted MR images, obtained in a GE Signa 1.5 T MRI scanner, were used as an individual anatomical template for each monkey, and mean PET images were coregistered to the MR images using PMOD 3.0 (PMOD group. Zurich, Switzerland). Regions of interest (ROI) were defined manually on the reoriented MR images. ROIs were drawn for the occipital cortex, prefrontal cortex, globus pallidus, caudate nucleus, putamen, midbrain, hippocampus, cerebellum, and whole brain. All calculations were based on the assumption that radioactivity in brain represents unchanged radioligand. Regional radioactivity concentrations were decay-corrected and expressed as percent of the standard uptake value (%SUV), calculated as (percent of injected radioactivity/brain tissue (cm 3 )) Â body weight (g). The cerebellum is a region with negligible density of 5-HT 1B receptors (Varnä s et al., 2001) and was used as an approximate for free and nonspecifically bound radioligand concentration in the brain. Specific binding to 5-HT 1B receptors was defined as the difference between the total radioactivity concentration in high-density regions and cerebellum. The specific binding ratio was defined as the ratio of specific binding to the radioactivity in cerebellum. The mean specific binding ratio (SBR) was calculated by using the area under the curve (AUC) for the time interval 45-123 min.
RESULTS
For the 12 PET-measurements, the mean injected radioactivity of [ 11 C]AZ10419369 was 158 6 9 MBq (range: 141-174 MBq), the mean specific radioactivity was 500 GBq/mmol (range: 190-694 GBq/mmol), and the mean injected mass was 0.16 mg (range: 0.11-0.37 mg). Receptor occupancy by the radioligand was calculated for the highest injected mass. Assuming a mean 5-HT 1B receptor density of 10 nM in monkey (Tomasi et al., 2008), the injected mass was estimated to result in radioligand receptor occupancy not higher than 2% and was thus not viewed as a confounder.
After i.v. administration of [ 11 C]AZ10419369 at baseline conditions, the regional distribution of radioactivity was in agreement with previous measurements in nonhuman primates and man (Pierson et al., 2008) . Uptake of radioactivity was high in globus pallidus, occipital cortex, and midbrain; moderate in striatum, thalamus, prefrontal cortex, and hippocampus; and low in cerebellum (Fig. 1) . In all regions, besides the cerebellum, the time curve for specific binding peaked within 30 min after radioligand injection and the ratio of specific binding to the cerebellum reached a plateau within 50 min.
There was an evident decrease in [ 11 C]AZ10419369 binding after administration of fenfluramine (Fig. 1) . There was no evident effect of fenfluramine on the radioactivity concentration in the cerebellum, whereas there was a rapid decrease in specific [ 11 C]AZ10419369 binding in all other regions examined (Fig. 2) . The effect appeared dose-dependent because the decrease was more pronounced after fenfluramine 5 mg/kg than after 1 mg/kg.
Changes in specific binding ratios were at a rather constant level from 45 to 123 min after radioligand injection, and this time interval was used in an initial attempt to quantify the effect of fenfluramine (Fig. 2C) . After fenfluramine, the SBR-values decreased in a dosedependent fashion in all three monkeys, with a regional average of 27% at 1 mg/kg and 50% at 5 mg/kg. There was no evident difference between brain regions with regard to the effect of fenfluramine ( Fig. 3 ; Table I ).
DISCUSSION
The study showed that the binding of [ 11 C]AZ10419369 to the 5HT 1B -receptor decreased in a dose-dependent manner after administration of fenfluramine. The test compound fenfluramine has dual action as a 5-HT releasing agent and reuptake inhibitor, and has previously been used as a tool in experimental studies evaluating the effect of changes in 5-HT levels on radioligand binding (Hume et al., 2001; Maeda et al., 2001; Zimmer et al., 2002) . Microdialysis studies in unanesthetized monkeys have shown that i.v. doses of 5 and 10 mg/kg (6) binding. Such competition is however less plausible since d-fenfluramine has been reported to have very low affinity (16.30 lM; IC 50 ) to the 5-HT 1B receptor in rodents (Mennini et al., 1991) . This view is further supported by the observation that fenfluramine has higher 5-HT 1A receptor affinity (3.73 lM; IC 50 ) (Mennini et al., 1991) , but no effect on [ (Janoshazi et al., 2007) . Although such effects remain to be confirmed in intact neuronal tissue, it cannot be excluded that rapid internalization may contribute to the presently observed reductions in (Sayer et al., 1999) , but this effect may be considered minimal when applying an acute drug challenge as in the present displacement study.
The here reported sensitivity of [ 11 C]AZ10419369 binding to altered 5-HT levels is greater than that reported for antagonist radioligands targeting the 5-HT 1A receptor (Derry et al., 2006; Praschak-Rieder et al., 2004; Sibon et al., 2008; Udo de Haes et al., 2002 . This discrepancy may relate to differences in receptor subtype characteristics such as affinity of 5-HT, regional distribution or cellular localization. Interestingly, this difference is not unique since a series of similar observations have been consistently reported for drug challenges of D 1 -and D 2 -receptor binding, respectively (Laruelle, 2000) . Future work is needed to tackle these challenging and interesting observations in more detail.
A confounder in this study could be the use of anesthesia. 5-HT release has been shown to be decreased in rats during slow-wave sleep and isoflurane anesthesia (Mukaida et al., 2007) . To minimize this potential confounder, the same anesthesia and experimental conditions were maintained in baseline and displacement conditions. In this study, anesthesia was, for technical reasons, maintained with i.v. infusion of ketamine and xylazine on one of the six experimental days. The effect on [ 11 C]AZ10419369 binding was however similar to that in the other experiments suggesting no obvious relationship between the effect of fenfluramine on 5-HT levels and sevoflurane use.
The present development of [ 11 C]AZ10419369 as a radioligand being sensitive to endogenous 5-HT levels requires further confirmation. Quantitative analyses are warranted to control for potential confounding fenfluramine-induced changes in regional blood flow. Future human studies will clarify the potential confounding role of anesthesia. The ultimate aim is to develop a useful radioligand for clinical research on the pathophysiology and treatment of major psychiatric conditions such as depression and anxiety. This study in cynomolgus monkeys shows that [ 11 C]AZ10419369 binding to 5-HT 1B -receptors has potential to serve as such a tool.
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